Deng L Y, Schiffrin E L
MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
J Cardiovasc Pharmacol. 1998;31 Suppl 1:S380-3. doi: 10.1097/00005344-199800001-00108.
Spontaneously hypertensive rats (SHR), renovascular hypertensive rats [two-kidney one clip Goldblatt (2-K 1C) and 1-K 1C], and SHR treated with the nitric oxide (NO) synthase inhibitor N omega-nitro-L-arginine methyl ester (L-NAME), do not respond to endothelin (ET) receptor antagonists with a decrease in blood pressure. However, treatment with ET receptor antagonists has shown some beneficial renal and coronary effects in SHR. In this study we examined tissues from SHR, L-NAME-treated SHR, 2-K 1C, and 1-K 1C, using in situ hybridization with a specific rat preproET-1 cRNA probe to evaluate preproET-1 mRNA abundance in blood vessels, heart, and kidneys. Grain density was similar in SHR and Wistar-Kyoto (WKY) rats in all tissues examined. L-NAME-treated SHR showed increased grain density vs. SHR in endothelium of aorta and of small coronary arteries and in kidney glomeruli, but not in renal or mesenteric arteries. 2-K 1C presented increased grain density in coronary arteries and in glomeruli of the unclipped but not the clipped kidney vs. glomeruli of control rats. 1-K 1C rats exhibited increases in preproET-1 mRNA relative to unilaterally nephrectomized control rats in endothelium of aorta and in mesenteric and coronary arteries, but not in renal arteries or glomeruli. None of the hypertensive models studied showed detectable evidence of myocardial overexpression of preproET-1 mRNA. Therefore, tissue-specific enhancement of ET-1 expression may underlie ET-dependent functional alterations and may explain the beneficial effects of ET receptor antagonists in the coronary circulation or in the kidney in some hypertensive models, but not in SHR.
自发性高血压大鼠(SHR)、肾血管性高血压大鼠[两肾一夹戈德布拉特(2-K 1C)和1-K 1C],以及用一氧化氮(NO)合酶抑制剂Nω-硝基-L-精氨酸甲酯(L-NAME)处理的SHR,对内皮素(ET)受体拮抗剂无血压降低反应。然而,ET受体拮抗剂治疗已在SHR中显示出一些有益的肾脏和冠状动脉效应。在本研究中,我们使用特异性大鼠前体ET-1 cRNA探针进行原位杂交,以评估SHR、L-NAME处理的SHR、2-K 1C和1-K 1C的血管、心脏和肾脏组织中前体ET-1 mRNA的丰度。在所检查的所有组织中,SHR和Wistar-Kyoto(WKY)大鼠的颗粒密度相似。与SHR相比,L-NAME处理的SHR在主动脉和小冠状动脉内皮以及肾小体中颗粒密度增加,但在肾动脉或肠系膜动脉中未增加。与对照大鼠的肾小球相比,2-K 1C在未夹闭肾脏的冠状动脉和肾小球中颗粒密度增加,但夹闭肾脏的肾小球中未增加。与单侧肾切除的对照大鼠相比,1-K 1C大鼠在主动脉内皮以及肠系膜和冠状动脉中前体ET-1 mRNA增加,但在肾动脉或肾小球中未增加。所研究的高血压模型均未显示出前体ET-1 mRNA在心肌中过度表达的可检测证据。因此,ET-1表达的组织特异性增强可能是ET依赖性功能改变的基础,并且可以解释ET受体拮抗剂在某些高血压模型的冠状动脉循环或肾脏中的有益作用,但在SHR中并非如此。